Prasad Kulkarni on dengue monoclonal antibodies

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.Read the full article:https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninfContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Om Podcasten

Saleha Hassan, Senior Editor at The Lancet Infectious Diseases, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from polio eradication in Africa to COVID-19 vaccines in Hong Kong, the treatment of early syphilis in adults to Mpox in the UK, and more.